Therapeutic Effect of Pidotimod on Mycoplasma Pneumoniae Pneumonia in Children and Changes of Their Immune Function

MA Hong-qiu,LI Li,XU Yong,MA Shao-jie,XIN De-li
2010-01-01
Abstract:Objective To explore the changes of immune function in children with mycoplasma pneumoniae pneumonia(MPP) and the-rapeutic effects of pidotimod.Methods T-lymphocyte subsets of 35 children with MPP in Department of Pediatrics of Beijing Friendship Hospital Affiliated to Capital Medical University from Mar.2005 to Dec.2006 were detected by flow cytometry,meanwhile 9 cases of healthy children as healthy control group.Children with MPP were divided to 2 groups:pidotimod therapy group and general therapy group.The children in pidotimod therapy group treated with azithromycin intravenous injection(10 mg·kg-1·d-1) and oral pidotimod.The general therapy group only treated with axithromycin intravenous injection.The therapy time were 3-5 days.The changes of T-lymphocyte subsets between MPP group and healthy control group,pidotimod therapy group and general therapy group were compared.SPSS 11.2 software was used to analyze the data.Results Compared with healthy control group,the levels of CD4+ and CD4+/CD8+ of children in MPP group were decreased(Pa<0.05),levels of CD19+ increased(P<0.05).Compared with general therapy group,levels of CD4+ and CD4+/CD8+ in pidotimod therapy group increased(Pa<0.05).Conclusions T-lymphocyte subsets decreased and B-lymphocyte subsets increased in children with MPP.Pidotimod can up-regulate levels of CD4+,amd improve pneumoniae recovery.
What problem does this paper attempt to address?